ReferenceID 2645
Platycodin D inhibits the malignant progression of papillary thyroid carcinoma by NF-κB and enhances the therapeutic efficacy of pembrolizumab
Drug Dev Res
Papillary thyroid carcinoma (PTC) is the most common pathological type of thyroid cancer. Studies have shown that platycodin D has several pharmacological effects like anti-inflammatory, immunomodulatory, and anti-tumor
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 2645
- Evidence Id
- 19235
- Core Evidence Id
- 19235
- Source Reference Id
- 5315
- Herb2 Reference Id
- HBREF006112
- Subject Paper Key
- HBIN040205_34859901
- Pubmed Id
- 34859901
- Doi
- 10.1002/ddr.21902
- Paper Title
- Platycodin D inhibits the malignant progression of papillary thyroid carcinoma by NF-κB and enhances the therapeutic efficacy of pembrolizumab
- Paper Abstract
- Papillary thyroid carcinoma (PTC) is the most common pathological type of thyroid cancer. Studies have shown that platycodin D has several pharmacological effects like anti-inflammatory, immunomodulatory, and anti-tumor effects, while the effect and mechanism of platycodin D on PTC are still unclear. This study was designed to investigate the effects of platycodin D on PTC by a series of in vitro and in vivo experiments. The results revealed that platycodin D inhibits PTC cell viability and clonal levels and affects PTC cell cycle. Platycodin D promotes apoptosis in PTC cells. Furthermore, it inhibits the activation of NF-κB signaling pathway and affects cell growth. Platycodin D inhibits PD-L1 expression and enhances the effect of pembrolizumab on PTC cells. In conclusion, platycodin D can effectively block the progression of PTC through the NF-κB signaling pathway, accompanied by cell cycle arrest and enhanced cell apoptosis. In vitro and in vivo, platycodin D was shown to enhance pembrolizumab's sensitivity to PTC. Platycodin D is a promising monomer for therapy of PTC, providing references for future research on PTC treatment.
- Journal
- Drug Dev Res
- Publish Year
- 2021
- Experiment Subject
- Experiment Type
- Animal & Cell Experiment
- Phenotype Related
- Papillary Thyroid Carcinoma; Thyroid Cancer
- Paper Title Cn
- Paper Title En
- Platycodin D inhibits the malignant progression of papillary thyroid carcinoma by NF-κB and enhances the therapeutic efficacy of pembrolizumab
- Bilingual Status
- semi_complete